|
Genzyme makes big money off small-time diseases. The company's product portfolio focuses on rare genetic disorders as well as kidney disease, cancer, and biosurgery. One of its main products, Cerezyme, is a leading (and pricey) treatment for Gaucher's disease, a rare enzyme-deficiency condition. Founded in 1981, Genzyme also is involved in drug development and genetic testing and other services. In addition, the company develops gene-based cancer diagnosis and treatment products, renal care therapies, and orthopedic biological surgery products. Genzyme's products are sold to healthcare professionals in some 100 countries, primarily through wholesale distributors.
|
| | | Contact Information | |
Address: |
500 Kendall St.
Cambridge, MA 02142
| | Phone: | 617-252-7500 | | Fax: | 617-252-7600 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 4605.00 M | | Revenue Growth (1 yr): | 20.80% | | Employees (2008): | 11,000 | | Employee Growth (1 yr): | 10.00% |
|
|
Key People
| | • |
Chairman, President, and CEO:
Henri A. Termeer
| | • |
EVP Finance and CFO:
Michael S. Wyzga
| | • |
SVP Government Relations:
Mary McGrane
|
|
|
